Clinical Trials Logo

Multiple Myeloma Progression clinical trials

View clinical trials related to Multiple Myeloma Progression.

Filter by:
  • None
  • Page 1

NCT ID: NCT03706547 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Start date: October 30, 2018
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory multiple myeloma.

NCT ID: NCT03687125 Terminated - Clinical trials for Multiple Myeloma in Relapse

Tinostamustine Conditioning and Autologous Stem Cell

TITANIUM1
Start date: October 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 The primary objectives of Phase 1 of this study are to: - Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen. - Identify the recommended Phase 2 dose (RP2D) of tinostamustine for use in the Phase 2 portion of the study. The secondary objective of Phase 1 of this study is to: - Investigate the pharmacokinetics (PK) of tinostamustine.

NCT ID: NCT03672253 Active, not recruiting - Multiple Myeloma Clinical Trials

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Start date: July 26, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, single-center, phase 1 study, to determine the safety and efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after previous CAR-T cell therapy.

NCT ID: NCT03601624 Recruiting - Clinical trials for Refractory Multiple Myeloma

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans

MM-POM-2018
Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Despite available therapies, MM uniformly fatal and participants who have received prior lenalidomide (Len) and bortezomib have a median overall survival (OS) of 9 months. Pomalidomide (Pom) plus low-dose dexamethasone (Dex) significantly improved efficacy parameters in terms of progression free survival (PFS), OS, and overall response (ORR) compared with high-dose Dex in participants with refractory or relapsed, and refractory MM, including participants with disease refractory to both bortezomib and lenalidomide. Alkylating agents also represent standard therapies for participants with MM. There are some reports demonstrating combination of Len and continuous cyclophosphamide (Cy) achieve an ORR of 50% in Len refractory participants, suggesting Cy may be able to overcome resistance to Len. The investigators aimed to assess the safety in Mexican MM participants in relapse/refractory stage of the triple combination: IV Cy in combination with Pom plus Dex until disease progression. A multicenter study is proposed. Primary endpoint: Safety. Efficacy as secondary endpoint: PF, OS and ORR.

NCT ID: NCT03428373 Active, not recruiting - Clinical trials for Multiple Myeloma in Relapse

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

RithMM
Start date: January 17, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy. The pilot feasibility study was conducted in preparation for this randomized controlled trial designed to assess the effect of an intervention.